ArticleNPJ vaccines2020
Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle.
Article in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 33 citations in OpenAlex.
- Induction of a Th1-Type Polyfunctional T-Cell Response by the Four-segmented Rift Valley Fever Candidate Vaccine in Humans.The Journal of infectious diseases · 2026Article
- Efficient Sensing of a 4-Segmented Rift Valley Fever Virus Vaccine Candidate by Human Monocytes.The Journal of infectious diseases · 2026Article
- Development of reference material from Rift Valley fever virus RNA.Virology journal · 2026Article
- A Species-Independent Lateral Flow Test to Detect Rift Valley Fever Virus Antibodies Using a Double Antigen Approach.Viruses · 2026Article
- Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review.PLoS neglected tropical diseases · 2026Article
- The Dissemination of Rift Valley Fever Virus to the Eye and Sensory Neurons of Zebrafish Larvae Is Stat1-Dependent.Viruses · 2025Article
- Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice.Emerging microbes & infections · 2024Article
- Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis.JCI insight · 2024Article
- Quantification of RVFV Specific T Cell Responses in Mice Pre-immunized with Potential Vaccine Candidates.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.NPJ vaccines · 2023Review
- Rift Valley Fever Virus-Infection, Pathogenesis and Host Immune Responses.Pathogens (Basel, Switzerland) · 2023Review
- Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use.Vaccines · 2023Review
- Comparison of RT-qPCR and RT-ddPCR with Rift valley fever virus (RVFV) RNA.Scientific reports · 2023Article
- Quantifying Rift Valley fever virus transmission efficiency in a lamb-mosquito-lamb model.Frontiers in cellular and infection microbiology · 2023Article
- Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome.Viral immunology · 2023Article
- Natural hosts and animal models for Rift Valley fever phlebovirus.Frontiers in veterinary science · 2023Review
- Article
- Incomplete bunyavirus particles can cooperatively support virus infection and spread.PLoS biology · 2022Article
- Review
- Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes.Transboundary and emerging diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rift Valley fever virus (RVFV) is a mosquito-borne bunyavirus that causes severe and recurrent outbreaks on the African continent and the Arabian Peninsula and continues to expand its habitat. RVFV induces severe disease in newborns and abortion in pregnant ruminants. The viral genome consists of a small (S), medium (M) and large (L) RNA segment of negative polarity. The M segment encodes a glycoprotein precursor protein that is co-translationally cleaved into the two structural glycoproteins Gn and Gc, which are involved in receptor attachment and cell entry. We previously constructed a four-segmented RVFV (RVFV-4s) by splitting the M genome segment into two M-type segments encoding either Gn or Gc. RVFV-4s replicates efficiently in cell culture but was shown to be completely avirulent in mice, lambs and pregnant ewes. Here, we show that a RVFV-4s candidate vaccine for veterinary use (vRVFV-4s) does not disseminate in vaccinated animals, is not shed or spread to the environment and does not revert to virulence. Furthermore, a single vaccination of lambs, goat kids and calves was shown to induce protective immunity against a homologous challenge. Finally, the vaccine was shown to provide full protection against a genetically distinct RVFV strain. Altogether, we demonstrate that vRVFV-4s optimally combines efficacy with safety, holding great promise as a next-generation RVF vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.